Dr. Wong joined The Column Group in 2022 as a Venture Partner. He is CEO of RAPT Therapeutics. Prior to RAPT, he served as Senior Vice President, Research, and Head of Immuno-Oncology at Five Prime Therapeutics. Prior to FivePrime, Dr. Wong served as Director in the Inflammation Disease Biology Area at Roche. There, he led […]
Brian Wong, MD, PhD Read More »
Dr. Hui Tian joined The Column Group in 2022 as a Venture Partner. Previously he was a founding member of NGM Biopharmaceuticals and most recently served as Senior Vice President of Research. In this role, he was responsible for discovery research across multiple therapeutic areas including metabolic diseases, retinal diseases and cancer. In a span
Jeff Goater joined The Column Group as a Venture Partner in 2021. Previously, he served as Chief Executive Officer of Surface Oncology. During his tenure at Surface, the company fostered an award-winning culture, advanced four programs into clinical development, completed its initial public offering and secured multiple strategic collaborations, including a transformative partnership with GlaxoSmithKline.
Dr. Hymowitz joined The Column Group in 2021. Previously, she spent 22 years at Genentech rising to Vice President of Protein Sciences. In this role, she oversaw the large molecule drug discovery portfolio and mentored project teams on the identification and optimization of more than 35 clinical candidates. Earlier, as a member of the Genentech
Sarah Hymowitz, PhD Read More »
Dr. Ray joined The Column Group in 2017. Previously, Dr. Ray was an Associate of Business Development at Foghorn Therapeutics, which she helped launch with Flagship Pioneering. Dr. Ray helped develop and execute the scientific, business and operating plans for Foghorn Therapeutics. Dr. Ray helped establish the first onsite next-generation sequencers for Ebola viral surveillance
Mr. Evangelista joined The Column Group in 2012 and has almost two decades of venture capital industry experience. Previously, he was with Three Arch Partners, and prior to that, Lightspeed Venture Partners. He began his career working for several large money management firms including Fisher Investments and Barclays Global Investors. Mr. Evangelista is a Certified
Dr. Josey joined The Column Group as a Venture Partner in 2020. Previously he served as the President, Chief Executive Officer and a member of the Board of Directors of Peloton Therapeutics, Inc., from 2013 until its acquisition by Merck in 2019. He joined Peloton in 2011 as the first employee in the role of
Dr. Chen joined The Column Group in 2019. Previously, he was a Venture Partner at OrbiMed focusing on company creation and investing in early stage biotech companies. In this capacity he took on interim management roles at E-Scape Bio, TranscripTx and Adicet. He also served on the board of Pionyr Immunotherapeutics and Logic Bio. Prior
Dr. Lasky joined The Column Group in 2014. He has worked in the biotechnology industry for over 30 years. In 1981, he was a founding scientist of Genetics Institute, acquired by Wyeth, one of the earliest biotechnology companies. He was subsequently a leading scientist at Genentech and eventually a Genentech Fellow. He worked in various
